Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Gynecologic 2Gastrointestinal 2

Conditions

Pancreatic Neoplasms 3Ovarian Neoplasms 2Mesothelioma, Malignant 2Mesothelioma 2Carcinoma, Non-Small-Cell Lung 2Severe combined immunodeficiency with sensitivity to ionizing radiation 1Neoplasms 1

Interventions

pembrolizumab 15Pemetrexed 15Cisplatin 12Nivolumab 9Carboplatin 8Ipilimumab 7tazemetostat 3fludarabine 3anetumab ravtansine 3Cyclophosphamide 3spartalizumab 2budigalimab 2belinostat 2atezolizumab 2amatuximab 2Vinorelbine 2Paclitaxel 2Gemcitabine 2Docetaxel 2venetoclax 1vandetanib 1trametinib 1tocilizumab 1tislelizumab 1sotorasib 1ruxolitinib 1rovalpituzumab tesirine 1ribociclib 1rebastinib 1osimertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Mesothelioma × amatuximab × Clear all
NCT01521325 2016-09-30

A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers

Morphotek

Phase 1 Completed
6 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT00325494 2014-07-17

A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer

Morphotek

Phase 1 Completed
24 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡